Stock Watch: Rollercoaster For Pfizer; Doldrums For Esperion
Commercial Success And Failure During The Pandemic
Executive Summary
An early high for Pfizer with its strong first-quarter results was followed by patent waiver worries. At the other end of the spectrum, Esperion reminded us of the challenges in making a commercial success as a small biopharma firm in the pandemic.